No more fracture trials in osteoporosis?

Affiliations

¹ Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand; Auckland District Health Board, Auckland, New Zealand. Electronic address: i.reid@auckland.ac.nz.

Comment

Ian R Reid. Lancet Diabetes Endocrinol. 2020 Aug.

. 2020 Aug;8(8):650-651.

doi: 10.1016/S2213-8587(20)30232-1.

¹ Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand; Auckland District Health Board, Auckland, New Zealand. Electronic address: i.reid@auckland.ac.nz.

No abstract available

Comment on

Treatment-related changes in bone mineral density as a surrogate biomarker for fracture risk reduction: meta-regression analyses of individual patient data from multiple randomised controlled trials.
Black DM, Bauer DC, Vittinghoff E, Lui LY, Grauer A, Marin F, Khosla S, de Papp A, Mitlak B, Cauley JA, McCulloch CE, Eastell R, Bouxsein ML; Foundation for the National Institutes of Health Bone Quality Project. Black DM, et al. Lancet Diabetes Endocrinol. 2020 Aug;8(8):672-682. doi: 10.1016/S2213-8587(20)30159-5. Lancet Diabetes Endocrinol. 2020. PMID: 32707115